Atlas Trials

Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma

Clinical trial NCT06785415 · RECRUITING

Trial details

NCT number
NCT06785415
Sponsor
Mayo Clinic
Status
RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Recurrent Multiple Myeloma
Start date
2025-03-18
Primary completion
2031-04-01
Enrollment
37

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.